Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences:

Oppenheimer 36^th Annual Healthcare Life Sciences Conference
Format: Management will participate in a presentation and investor meetings
Date: Thursday, February 26, 2026
Presentation Time: 8:40 a.m. ET
Location: Virtual

TD Cowen 46^th Annual Health Care Conference
Format: Management will participate in a presentation and investor meetings
Date: Wednesday, March 4, 2026
Presentation Time: 1:50 p.m. ET
Location: Boston, MA

A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at investors.passagebio.com. A replay of the presentation will be available for 30 days following the event.

About Passage Bio

Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and advancement of cutting-edge, one-time therapies designed to target the underlying pathology of these conditions. Passage Bio’s lead product candidate, PBFT02, seeks to treat neurodegenerative conditions, including frontotemporal dementia, by elevating progranulin levels to restore lysosomal function and slow disease progression. 

To learn more about Passage Bio and our steadfast commitment to protecting patients and families against loss in neurodegenerative conditions, please visit: passagebio.com.

For further information, please contact:

Investors:
Stuart Henderson
Passage Bio
[email protected]

Passage Bio Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312.961.2502
[email protected]

You May Also Be Interested In

• Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
• Lithium Ionic Announces Agreement to Sell its Salinas Group of Lithium Properties to PLS for US$37.5 Million in Cash, Retaining a 2.0% Royalty on Future Spodumene Sales
• Project Pigeon Consortium Launches APAC Working Group to Advance Governance Standards for Permissionless Blockchains